E Losada1,2, B Soldevila3,4,5, M S Ali6,7, D Martínez-Laguna8,9,10, X Nogués10,11, M Puig-Domingo2,3,4,5, A Díez-Pérez10,11, D Mauricio12,13,14,15, D Prieto-Alhambra6,8,10. 1. Department of Endocrinology and Nutrition, Hospital Can Misses, Eivissa, Spain. 2. Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Department of Endocrinology and Nutrition, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n. 08916, Badalona, Barcelona, Spain. 4. Fundació Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, Campus Can Ruti, Badalona, Barcelona, Spain. 5. CiBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. 6. Musculoskeletal Pharmaco- and Device Epidemiology, Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK. 7. Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 8. GREMPAL Research Group, IDIAP Jordi Gol, Universitat Autònoma de Barcelona, Barcelona, Spain. 9. Primary Care Barcelona, Institut Català de la Salut, Barcelona, Spain. 10. CIBER de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain. 11. Department of Internal Medicine, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain. 12. Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. didacmauricio@gmail.com. 13. Department of Endocrinology and Nutrition, Hospital Universitari Germans Trias i Pujol, Carretera del Canyet s/n. 08916, Badalona, Barcelona, Spain. didacmauricio@gmail.com. 14. Fundació Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, Campus Can Ruti, Badalona, Barcelona, Spain. didacmauricio@gmail.com. 15. CiBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. didacmauricio@gmail.com.
Abstract
We conducted a nested case-control study to study the association between antidiabetic treatments (alone or in combination) use and fracture risk among incident type 2 Diabetes mellitus patients. We found an increased risk of bone fracture with insulin therapy compared to metformin monotherapy. INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures, to which antidiabetic therapies may contribute. We aimed to characterize the risk of fracture associated with different antidiabetic treatments as usually prescribed to T2DM patients in actual practice conditions. METHODS: A case-control study was nested within a cohort of incident T2DM patients registered in 2006-2012 in the Information System for Research Development in Primary Care (Catalan acronym, SIDIAP), a database which includes records for > 5.5 million patients in Catalonia (Spain). Each case (incident major osteoporotic fracture) was risk-set matched with up to five same-sex controls by calendar year of T2DM diagnosis and year of birth (± 10 years). Study exposure included previous use of all antidiabetic medications (alone or in combination), as dispensed in the 6 months before the index date, with metformin (MTF) monotherapy, the most commonly used drug, as a reference group (active comparator). RESULTS: Data on 12,277 T2DM patients (2049 cases and 10,228 controls) were analyzed. Insulin use was associated with increased fracture risk (adjusted OR 1.63 (95% CI 1.30-2.04)), as was the combination of MTF and sulfonylurea (SU) (adjusted OR 1.29 (1.07-1.56)), compared with MTF monotherapy. Sensitivity analyses suggest possible causality for insulin therapy but not for the MTF + SU combination association. No significant association was found with any other antidiabetic medications. CONCLUSIONS: Insulin monotherapy was associated with an increased fracture risk compared to MTF monotherapy in T2DM patients. Fracture risk should be taken into account when starting a glucose-lowering drug as part of T2DM treatment.
We conducted a nested case-control study to study the association between antidiabetic treatments (alone or in combination) use and fracture risk among incident type 2 Diabetes mellituspatients. We found an increased risk of bone fracture with insulin therapy compared to metformin monotherapy. INTRODUCTION:Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures, to which antidiabetic therapies may contribute. We aimed to characterize the risk of fracture associated with different antidiabetic treatments as usually prescribed to T2DM patients in actual practice conditions. METHODS: A case-control study was nested within a cohort of incident T2DM patients registered in 2006-2012 in the Information System for Research Development in Primary Care (Catalan acronym, SIDIAP), a database which includes records for > 5.5 million patients in Catalonia (Spain). Each case (incident major osteoporotic fracture) was risk-set matched with up to five same-sex controls by calendar year of T2DM diagnosis and year of birth (± 10 years). Study exposure included previous use of all antidiabetic medications (alone or in combination), as dispensed in the 6 months before the index date, with metformin (MTF) monotherapy, the most commonly used drug, as a reference group (active comparator). RESULTS: Data on 12,277 T2DM patients (2049 cases and 10,228 controls) were analyzed. Insulin use was associated with increased fracture risk (adjusted OR 1.63 (95% CI 1.30-2.04)), as was the combination of MTF and sulfonylurea (SU) (adjusted OR 1.29 (1.07-1.56)), compared with MTF monotherapy. Sensitivity analyses suggest possible causality for insulin therapy but not for the MTF + SU combination association. No significant association was found with any other antidiabetic medications. CONCLUSIONS: Insulin monotherapy was associated with an increased fracture risk compared to MTF monotherapy in T2DM patients. Fracture risk should be taken into account when starting a glucose-lowering drug as part of T2DM treatment.
Entities:
Keywords:
Epidemiology; Fracture risk; General population; Type 2 diabetes mellitus
Authors: M Del Mar García-Gil; Eduardo Hermosilla; Daniel Prieto-Alhambra; Francesc Fina; Magdalena Rosell; Rafel Ramos; Jordi Rodriguez; Tim Williams; Tjeerd Van Staa; Bonaventura Bolíbar Journal: Inform Prim Care Date: 2011
Authors: Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741
Authors: Jetty A Overbeek; Edith M Heintjes; Daniel Prieto-Alhambra; Patrick Blin; Régis Lassalle; Gillian C Hall; Francesco Lapi; Elisa Bianchini; Niklas Hammar; Irene D Bezemer; Ron M C Herings Journal: Clin Ther Date: 2017-03-23 Impact factor: 3.393
Authors: Dori Bilik; Laura N McEwen; Morton B Brown; Nathan E Pomeroy; Catherine Kim; Keiko Asao; Jesse C Crosson; O Kenrik Duru; Assiamira Ferrara; Victoria C Hsiao; Andrew J Karter; Pearl G Lee; David G Marrero; Joe V Selby; Usha Subramanian; William H Herman Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958
Authors: Preethi Srikanthan; Carolyn J Crandall; Dana Miller-Martinez; Teresa E Seeman; Gail A Greendale; Neil Binkley; Arun S Karlamangla Journal: J Bone Miner Res Date: 2014-04 Impact factor: 6.741
Authors: Richard H Lee; Richard Sloane; Carl Pieper; Kenneth W Lyles; Robert A Adler; Courtney Van Houtven; Joanne LaFleur; Cathleen Colón-Emeric Journal: J Bone Miner Res Date: 2019-10-09 Impact factor: 6.741
Authors: C Eller-Vainicher; E Cairoli; G Grassi; F Grassi; A Catalano; D Merlotti; A Falchetti; A Gaudio; I Chiodini; L Gennari Journal: J Diabetes Res Date: 2020-05-22 Impact factor: 4.011